Insilico Medicine, a global artificial intelligence (AI)–driven drug discovery company, has entered into a multi-year research and development collaboration with Servier, an independent international pharmaceutical group governed by a foundation. The strategic alliance aims to identify and develop novel oncology therapeutics targeting difficult-to-drug biological pathways, using Insilico’s proprietary AI platform, Pharma.AI.
Under the terms of the agreement, Insilico will be eligible to receive up to US$32 million in upfront and near-term research and development payments. The company will lead the AI-powered discovery and early development of potential drug candidates that meet predefined scientific and development criteria. Servier will share R&D costs and assume responsibility for clinical validation and global commercialization, reflecting a complementary division of expertise between the two partners.
The collaboration highlights Servier’s growing focus on applying advanced technologies to accelerate innovation in areas of high unmet medical need, particularly oncology. Christophe Thurieau, Executive Director of Research at Servier, said the partnership underscores the company’s confidence in Insilico’s internally developed and validated AI platform and its potential to generate high-quality drug candidates against challenging cancer targets.
Insilico’s leadership described the deal as further validation of the company’s AI-driven approach to pharmaceutical research. Alex Zhavoronkov, PhD, founder, CEO, and chief business officer of Insilico Medicine, noted that the collaboration reflects increasing industry recognition of generative AI as a core component of drug discovery. He added that deeper integration of AI across the pharmaceutical value chain could eventually enable AI systems to design experiments and make development decisions, accelerating timelines while improving efficiency and safety.
The partnership builds on Insilico’s established track record in oncology drug discovery and development. The company has assembled a broad oncology pipeline addressing multiple cancer indications through a mix of novel and well-validated biological mechanisms. Among its leading programs are ISM6331, a potential best-in-class pan-TEAD inhibitor, and ISM3412, a MAT2A inhibitor. Both assets are currently being evaluated in global, multicenter Phase I clinical trials. In addition, Insilico has out-licensed four other oncology programs, either fully or partially, to external partners, with Phase I trials underway.
Insilico’s use of AI and automation has also translated into measurable gains in preclinical efficiency. While traditional early-stage drug discovery typically takes an average of 4.5 years to reach preclinical candidate nomination, Insilico reported nominating 20 preclinical candidates between 2021 and 2024. The average timeline from project initiation to preclinical candidate nomination was reduced to 12 to 18 months per program, with only 60 to 200 molecules synthesized and tested.
As pharmaceutical companies continue to seek faster and more cost-effective approaches to drug development, the Insilico–Servier collaboration reflects a broader industry shift toward AI-enabled discovery as a means to tackle complex diseases such as cancer.